Theradux (recombinant modified human thioredoxin 1) / OrPro Therap - LARVOL DELTA

Development of Thioredoxin Monothiol Derivatives for Mitigating Radiation Induced Hematopoietic Injury (ASH 2023) - "We previously identified the stress-protective human thioredoxin-1 protein (TRX) as a novel molecule for enhancing HSC recovery in mouse models of radiation injury...In summary, we demonstrate that ORP100S, a monocysteinic, thioredoxin derivative, is a potent mitigator of radiation-induced hematopoietic injury even when delivered many hours post-exposure. Our preclinical study results support safety and efficacy with clear potential for this novel agent to advance to clinical studies for the treatment of acute radiation syndrome."

Aplastic Anemia • Hematological Disorders

Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation. (PubMed, Adv Sci (Weinh)) - "Human thioredoxin-1 (TRX) is a target-selective disulfide reductase with antioxidant, anti-inflammatory, and regulatory functions that mitigates cellular stresses in various organ systems, providing a compelling rationale for therapeutic use as a broad-spectrum cell protectant...Mechanistic studies revealed that ORP100S modulates the Kruppel-like factor 4 (KLF4)-p53 pathway to selectively inhibit ferroptosis in HSPCs but not cancer cells. These findings highlight the potential of ORP100S as a novel therapeutic agent for mitigating acute radiation injury and improving the safety and efficacy of chemotherapy without compromising antitumor activity."

Journal • Preclinical • Oncology • CSF2 • KLF4